Recently, ARID1A deficiency was shown to be associated with increased CD8 T-cell infiltration and expression of programmed death-ligand 1 (PD-L1) in ovarian cancer [2], implying the potential of ARID1A as a predictor of response to immune checkpoint inhibitors (ICIs). This evidence concerns the gene ARID1A and ovarian carcinoma.